Our patients are at the center of everything we do. That is why we are committed to working toward a healthier world for patients by solving some of the greatest challenges in medicine and transforming the standard of care of neurodegenerative diseases.

Our focus

Download our full 2016 Global Impact Report

Spotlight stories

Living (and Working) with MS

Some diseases are typically attributed to a certain demographic, which leads to misdiagnoses and wrong treatment as a result. See how Terrie Livingston, Biogen employee and MS patient, advocates for minority representation in the MS community.

Fostering Patient Engagement

Our patient advocacy teams work in collaboration with patient advocacy organizations and find ways to better serve the patients and caregivers. See how Elizabeth Stemporzewski, Senior Manager of Patient Advocacy, interacts with the spinal muscular atrophy (SMA) community and engages Biogen employees in understanding patient needs.

Goals and Performance

  • Over the past decade, nearly 20% of company revenues have been invested in R&D
  • Launched 1MSg®, a new MS campaign, to encourage MS patients to work with medical specialists and become even better informed
  • Created Together in SMA (spinal muscular atrophy), a disease education program to provide information about SMA and its symptoms
  • Received FDA approval of SPINRAZA® (nusinersen), the first therapy approved to treat children and adults with SMA
  • Ranked first on IDEA Pharma’s 2017 Product Innovation Index